Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
MY TRIALS
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Register a trial
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT04450342
Registration number
NCT04450342
Ethics application status
Date submitted
24/06/2020
Date registered
29/06/2020
Titles & IDs
Public title
REGENETEN™ Bioinductive Implant System in Full-thickness Tears
Query!
Scientific title
A Prospective, Multi-center, Randomized Controlled Study to Evaluate the Safety and Efficacy of ARCR Augmented With REGENETEN™ Bioinductive Implant System in Full-thickness Tears (Large or Massive) Repair Versus ARCR Alone
Query!
Secondary ID [1]
0
0
REGENETEN.2020.01
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
REGENETEN
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Rotator Cuff Injuries
0
0
Query!
Condition category
Condition code
Musculoskeletal
0
0
0
0
Query!
Other muscular and skeletal disorders
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Devices - Arthroscopic rotator cuff repair with REGENETEN™ Bioinductive Implant augmentation
Treatment: Surgery - Arthroscopic rotator cuff repair
Treatment: Devices - Arthroscopic rotator cuff repair for revision surgery
Experimental: ARCR augmented with REGENETEN™ Bioinductive Implant - During the ARCR procedure, the REGENETEN™ Bioinductive Implant is covering the tendon and attached to the bone and the tendon with small anchors.
Sham comparator: ARCR alone - The rotator cuff is repaired during arthroscopic standard procedure. No product is added for healing
Other: ARCR revision group - ARCR revision group allows treatment of subjects having recurrent tears, ARCR supplemented with REGENETEN
Treatment: Devices: Arthroscopic rotator cuff repair with REGENETEN™ Bioinductive Implant augmentation
The Arthroscopic rotator cuff repair aims at repairing the rotator cuff following tendon tear. The REGENETEN Bioinductive Implant is a medical device intended for the management and protection of tendon injuries. The REGENETEN Bioinductive Implant is indicated for the management and protection of rotator cuff tendon injuries in which there has been no substantial loss of tendon tissue. The REGENETEN Bioinductive Implant is a bioabsorbable implant device that provides a layer of collagen over injured tendons. The implant is designed to provide a layer of collagen between a flat tendon and the surrounding tissue. After hydration, the implant is an easy-to-handle, pliable, nonfriable, porous collagen sheet.
Treatment: Surgery: Arthroscopic rotator cuff repair
The Arthroscopic rotator cuff repair aims at repairing the rotator cuff following tendon tear without supplement.
Treatment: Devices: Arthroscopic rotator cuff repair for revision surgery
The Arthroscopic rotator cuff repair can also occur in recurrent tears. The REGENETEN Bioinductive Implant will be applied during the ARCR procedure.
Query!
Intervention code [1]
0
0
Treatment: Devices
Query!
Intervention code [2]
0
0
Treatment: Surgery
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
6 months retear rate
Query!
Assessment method [1]
0
0
The cumulative 6 months retear rate after full-thickness ARCR augmented with REGENETEN versus ARCR alone. Failure is defined as Sugaya Type IV or V retear/recurrence (fullthickness discontinuity seen on both coronal and oblique sagittal MRI images).
Query!
Timepoint [1]
0
0
6 months post surgery
Query!
Secondary outcome [1]
0
0
Retear rate
Query!
Assessment method [1]
0
0
Cumulative 3, 6, 12, and 24 months retear rate after fullthickness ARCR augmented with REGENETEN (confirmed on MRI) versus ARCR alone. Failure is defined as Sugaya Type IV or V retear/recurrence (full-thickness discontinuity seen on both coronal and oblique sagittal MRI images).
Query!
Timepoint [1]
0
0
3, 6, 12, and 24 months
Query!
Secondary outcome [2]
0
0
Oxford Shoulder Score (OSS)
Query!
Assessment method [2]
0
0
The Oxford Shoulder Score (OSS) is a questionnaire for the assessment of outcomes of shoulder surgery, which can reduce the observer's errors in the evaluation. It contains 12- item patient-reported outcome (PRO) measures specifically designed and developed for assessing outcomes of shoulder surgery such as assessing the impact on patients' quality of life of degenerative conditions (e.g., arthritis and rotator cuff problems). The OSS consists of 12 questions each scored 0 to 4 (0=unbearable, 1=severe, 2=moderate, 3=mild, 4=none) with 4 representing the best outcome. When the 12 items are summed, this produces overall scores that run from 0 to 48, with zero (0) representing a severe shoulder problem and 48 representing no related problem. Higher scores represent better clinical outcomes.
Query!
Timepoint [2]
0
0
Baseline, 3, 6, 12 and 24 months
Query!
Secondary outcome [3]
0
0
Western Ontario Rotator Cuff (WORC)/Chinese version WORC (C-WORC) Index)
Query!
Assessment method [3]
0
0
The WORC/C-WORC Index is self-administered, and includes a 5 different domains (physical symptoms, sports and recreation, work, social function, and emotions). Each question uses a visual analog scale (VAS) representing a 100-point scale ranging from 0 to 100. The maximum score is 2100 (worst possible symptoms). Zero (0) represents no symptoms at all. The final score can also be presented as a percentage by subtracting the total from 2100, dividing by 2100, and multiplying by 100. This will give you an overall percentage. The total final WORC/CWORC Index scores can, therefore, range from 0% (lowest functional status level) to 100% (highest functional status level).
Query!
Timepoint [3]
0
0
Baseline, 3, 6, 12 and 24 months
Query!
Secondary outcome [4]
0
0
Constant-Murley Score
Query!
Assessment method [4]
0
0
The Constant-Murley Score is a validated assessment of pain and shoulder functionality. The Constant Score is divided into 4 subscales: pain (15 points; VAS score range of 0-15), activities of daily living (20 points; range 0=worst, 5=best), strength (25 points; 1 point given per 0.5 kg of weights raised), and range of motion - forward flexion, external rotation, abduction and internal rotation of the shoulder (40 points; range 0=worst, 10=best). The higher the score, the higher the quality of function.
Query!
Timepoint [4]
0
0
Baseline, 3, 6, 12 and 24 months
Query!
Secondary outcome [5]
0
0
Subjective shoulder value (SSV)
Query!
Assessment method [5]
0
0
Overall performance of full-thickness ARCR augmented with REGENETEN versus ARCR alone at Baseline and at 3, 6, 12 and 24 months assessed by the Subjective Shoulder Value (SSV). The SSV is defined as a patient's subjective shoulder assessment expressed as a percentage of an entirely normal shoulder, which would score 100% (0% to 100% scale with 100% being normal).
Query!
Timepoint [5]
0
0
Baseline, 3, 6, 12 and 24 months
Query!
Secondary outcome [6]
0
0
EuroQol 5 Dimension 5 Level (EQ-5D-5L) Score
Query!
Assessment method [6]
0
0
The EQ-5D-5L score consists of two parts: a descriptive system and a visual analogue scale. The descriptive system is used to describe the subject's health state and consists of five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels to choose the most appropriate answer: no problems, slight problems, moderate problems, severe problems and extreme problems. The subject is asked to indicate his/her health state by marking the most appropriate statement in each of the five areas.
The visual analogue scale records the subject's self-rated health on a vertical visual analogue scale.The endpoints on the scale are labelled 'The best health you can imagine' and 'The worst health you can imagine'. The VAS can be used as a quantitative measure of health outcome as judged by the individual respondents.
Query!
Timepoint [6]
0
0
Baseline, 3, 6, 12 and 24 months
Query!
Secondary outcome [7]
0
0
Patient satisfaction Questionnaire Outcome
Query!
Assessment method [7]
0
0
The Patient Satisfaction Questionnaire is a simple subjective assessment of the success of surgery from the patient's perspective. Pre-Op: will be documented on a visual analogue score of 0-100. Rated by the subject with 0 is the least satisfied, 100 the most satisfied.Post-Op:This includes the VAS Patient Satisfaction Score as for pre-Op and additional five questions ask of the patient:1. How well did the surgery relieve the pain? 2. How well did the surgery increase your ability to perform regular activities? 3. How well did the surgery allow you to perform heavy work or sport activities (if allowed by Dr)? 4. How well did the surgery meet your expectations? Questions rated by the patient with excellent, very good,good, fair and poor. 5. Would you have the operation again if needed on another joint? Question rated by the patient with Definitely yes, Probably yes, Possibly not, Definitely not Rated by the subject with 0 is the least satisfied, 100 the most satisfied.
Query!
Timepoint [7]
0
0
Baseline, 3, 6, 12 and 24 months
Query!
Secondary outcome [8]
0
0
Pain, Visual analog scale (VAS) Score
Query!
Assessment method [8]
0
0
Overall performance of full-thickness ARCR augmented with REGENETEN versus ARCR alone at Baseline and at 3, 6,12 and 24 months assessed by the VAS Pain Score. Pain is assessed on a 100-point scale ranging from 0 to 100, with zero (0) representing no pain and 100 representing the worst pain imaginable
Query!
Timepoint [8]
0
0
Baseline, 2 weeks, 6 weeks, 3 and 6 months
Query!
Secondary outcome [9]
0
0
MRI Tendon Findings in ARCR augmented with REGENETEN versus ARCR alone via Sugaya Score postoperatively
Query!
Assessment method [9]
0
0
The Sugaya score will be used to determine postoperative cuff integrity through magnetic resonance imaging classified into 5 categories: Type I to Type V. Type I indicates sufficient thickness with homogenously low intensity. Type II indicates sufficient thickness with partial high intensity. Type III indicates insufficient thickness without discontinuity. Type IV indicates presence of a minor discontinuity, suggesting a small full-thickness tear. Type V indicates the presence of a major discontinuity, suggesting a medium or large full-thickness tear.
Query!
Timepoint [9]
0
0
Baseline, 3, 6, 12 and 24 months
Query!
Secondary outcome [10]
0
0
MRI Tendon Findings in ARCR augmented with REGENETEN versus ARCR alone via Goutallier Classification postoperatively
Query!
Assessment method [10]
0
0
The Goutallier classification will be used to classify the fatty infiltration of the rotator cuff. The Goutallier classification ranges from a grade of 0 indicating a completely normal muscles without any fatty streaks to a grade of 4 which indicates that more fat than muscle is present.
Query!
Timepoint [10]
0
0
Baseline, 3, 6, 12 and 24 months
Query!
Secondary outcome [11]
0
0
Total tendon thickness, tendon length will be assessed by MRI Tendon Findings in ARCR augmented with REGENETEN versus ARCR alone postoperatively
Query!
Assessment method [11]
0
0
Tendon thickness, length will be assessed by MRI
Query!
Timepoint [11]
0
0
Baseline, 3, 6, 12 and 24 months
Query!
Secondary outcome [12]
0
0
Size of retear: anteroposterior [AP]/mediolateral [ML]) postoperatively
Query!
Assessment method [12]
0
0
Size of retear will be based on MRI Tendon Findings in ARCR augmented with REGENETEN versus ARCR alone.
Query!
Timepoint [12]
0
0
Baseline, 3, 6, 12 and 24 months
Query!
Secondary outcome [13]
0
0
Shape of retear postoperatively
Query!
Assessment method [13]
0
0
Shape of retear will be based on MRI Tendon Findings in ARCR augmented with REGENETEN versus ARCR alone
Query!
Timepoint [13]
0
0
Baseline, 3, 6, 12 and 24 months
Query!
Secondary outcome [14]
0
0
Outcome of Return to Work Questionnaire in ARCR augmented with REGENETEN versus ARCR alone
Query!
Assessment method [14]
0
0
Generic questionnaire, covering work related questions,including demographics on laborer/sedentary.
Query!
Timepoint [14]
0
0
Baseline, 2 weeks, 6 weeks, 3, 6, 12 and 24 months
Query!
Secondary outcome [15]
0
0
Cumulative duration of opioid use in ARCR augmented with REGENETEN versus ARCR alone
Query!
Assessment method [15]
0
0
Self-reported opioid use diary completed by the patient on a daily basis, from day 0-14, documenting opioid use. Consumption daily (YES/NO) x14 days, 'Have you taken any opioid medication today for shoulder pain?' Y/N .
Query!
Timepoint [15]
0
0
2 weeks
Query!
Secondary outcome [16]
0
0
Total operative time ARCR augmented with REGENETEN versus ARCR alone
Query!
Assessment method [16]
0
0
Total operative time ARCR augmented with REGENETEN versus ARCR alone.
Query!
Timepoint [16]
0
0
Intra-operative time
Query!
Secondary outcome [17]
0
0
Sling type and mobilization time in ARCR augmented with REGENETEN versus ARCR alone
Query!
Assessment method [17]
0
0
The type of sling will be collected and presented for each treatment arm summarizing if standard sling, shoulder immobilizer, abduction sling, ER sling, or other were advised and mobilization time will be calculated for both arms summarizing mobilization duration.
Query!
Timepoint [17]
0
0
3 months
Query!
Eligibility
Key inclusion criteria
1. Subject requires Arthroscopic rotator cuff repair (ARCR);
2. Subjects with a diagnosis of a symptomatic primary or recurrent (revision repair subject group), large or massive tear (= 3 cm AP/ML) of the supraspinatus and/or infraspinatus tendons amenable to repair. For screening purposes, a = 2 cm AP/ML tear as measured on MRI will be eligible to proceed to the operative visit but will have to be confirmed as = 3 cm on arthroscopy using a calibrated probe to proceed;
3. Subject is > 40 years of age (no upper limit);
4. Subject provides written informed consent for study participation using an Independent Ethical Committee (IEC) / Institutional Review Board (IRB) approved consent form;
5. Subject is willing and able to participate in required follow-up visits and is able to complete study activities.
Query!
Minimum age
40
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
1. Subjects who are unable to tolerate magnetic resonance imaging (MRI), due to psychiatric or medical contraindications;
2. Subjects with Samilson-Prieto osteoarthritis > 2;
3. Subjects with current or prior infection of the ipsilateral shoulder;
4. Subjects with known hypersensitivity to bovine-derived materials;
5. Subjects with known inflammatory arthropathy, history of inflammatory arthropathy, or chronic joint disease;
6. Subjects with prior shoulder surgery (not including rotator cuff repair [revision repair subject group only], biceps tenodesis/tenotomy, distal clavicle excision [DCE], subacromial decompression);
7. Subjects with an irreparable or partially reparable rotator cuff tear;
8. Subjects with a subscapularis tear requiring repair;
9. Subjects requiring a concomitant labral fixation procedure;
10. Subjects requiring a concomitant os acromiale fixation procedure;
11. Subjects with glenohumeral joint instability (multiple dislocations/subluxations);
12. Subjects with a subacromial or intra-articular injection within 3 months prior to surgery;
13. Subjects with condition(s) that contraindicate or complicate outcomes of ARCR e.g., > Hamada 3 rotator cuff arthropathy on X-ray, Goutallier atrophy > Grade 3, proximal humeral fracture or scapular fracture, avascular necrosis of the humeral head or glenoid, history of immunodeficiency disorders, history of chronic inflammatory disorders, oral or injected steroid use in last 4 weeks;
14. Subjects who are pregnant or breast feeding;
15. Subjects who are currently involved in any injury litigation or workers compensation claims;
16. Subjects who are enrolled, or plan to enroll, in another clinical trial during this study that would affect the outcomes of this study;
17. Subjects with a history of noncompliance with medical treatment, physical therapy (PT)/rehabilitation, or clinical study participation
18. Subject who, in the opinion of the Investigator, has an emotional or neurological condition that would pre-empt their ability or willingness to participate in the study including mental illness, mental retardation, and drug or alcohol abuse;
19. Subjects who do not meet the indication or are contraindicated according to specific Smith+Nephew REGENETEN System's Instructions for Use (IFUs);
20. Subject that meets the definition of a Vulnerable Subject per ISO14155:2020 Section 3.44.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
NA
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Stopped early
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
7/12/2020
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
31/10/2023
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
119
Query!
Recruitment in Australia
Recruitment state(s)
NSW,VIC
Query!
Recruitment hospital [1]
0
0
Macquarie University Hospital - Sydney
Query!
Recruitment hospital [2]
0
0
OrthoSport Victoria - Richmond
Query!
Recruitment postcode(s) [1]
0
0
2109 - Sydney
Query!
Recruitment postcode(s) [2]
0
0
3121 - Richmond
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Georgia
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Illinois
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Maryland
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
New York
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Ohio
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Texas
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Wisconsin
Query!
Country [8]
0
0
Canada
Query!
State/province [8]
0
0
New Brunswick
Query!
Country [9]
0
0
Canada
Query!
State/province [9]
0
0
Ontario
Query!
Country [10]
0
0
France
Query!
State/province [10]
0
0
Boulogne-Billancourt
Query!
Country [11]
0
0
France
Query!
State/province [11]
0
0
Provence-Alpes-Côte d'Azur
Query!
Country [12]
0
0
France
Query!
State/province [12]
0
0
Montpellier
Query!
Country [13]
0
0
France
Query!
State/province [13]
0
0
Paris
Query!
Country [14]
0
0
France
Query!
State/province [14]
0
0
Île-de-France
Query!
Country [15]
0
0
Hong Kong
Query!
State/province [15]
0
0
Hong Kong
Query!
Country [16]
0
0
Singapore
Query!
State/province [16]
0
0
Singapore
Query!
Country [17]
0
0
Switzerland
Query!
State/province [17]
0
0
Zurich
Query!
Country [18]
0
0
United Kingdom
Query!
State/province [18]
0
0
Lancashire
Query!
Country [19]
0
0
United Kingdom
Query!
State/province [19]
0
0
Manchester
Query!
Country [20]
0
0
United Kingdom
Query!
State/province [20]
0
0
Merseyside
Query!
Country [21]
0
0
United Kingdom
Query!
State/province [21]
0
0
Middlesex
Query!
Country [22]
0
0
United Kingdom
Query!
State/province [22]
0
0
Nottinghamshire
Query!
Country [23]
0
0
United Kingdom
Query!
State/province [23]
0
0
Warwickshire
Query!
Country [24]
0
0
United Kingdom
Query!
State/province [24]
0
0
West Midlands
Query!
Country [25]
0
0
United Kingdom
Query!
State/province [25]
0
0
Bristol
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Smith & Nephew, Inc.
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The study is designed to assess the safety and efficacy of Arthroscopic rotator cuff repair (ARCR) augmented with REGENETEN in subjects requiring full-thickness rotator cuff tear repair or revision repair versus Arthroscopic rotator cuff repair alone.
Query!
Trial website
https://clinicaltrials.gov/study/NCT04450342
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Chris Peach, MBBS MD FRCS (Tr&Orth)
Query!
Address
0
0
Manchester University NHS Foundation Trust
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
Query!
No/undecided IPD sharing reason/comment
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results not provided in
https://clinicaltrials.gov/study/NCT04450342